Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

September 30, 2023Courtney FlahertyPatients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class

Updated on: October 10,2023

Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

September 30, 2023Courtney FlahertyPatients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class

Updated on:October 10,2023

To stop spread of cancer, researchers target two signaling switches that trigger new blood vessel growth

byUniversity of East AngliaCredit: Unsplash/CC0 Public DomainHitting two targets at the same time may be the key to stopping the spread of aggressive cancers, according to new research from the

Updated on: January 08,2024

To stop spread of cancer, researchers target two signaling switches that trigger new blood vessel growth

byUniversity of East AngliaCredit: Unsplash/CC0 Public DomainHitting two targets at the same time may be the key to stopping the spread of aggressive cancers, according to new research from the

Updated on:January 08,2024

Early clinical trial results show 'dramatic and rapid' regression of glioblastoma after next generation CAR-T therapy

by Mass General BrighamCredit: Unsplash/CC0 Public DomainA collaborative project to bring the promise of cell therapy to patients with a deadly form of brain cancer has shown dramatic results amo

Updated on: March 20,2024

Early clinical trial results show 'dramatic and rapid' regression of glioblastoma after next generation CAR-T therapy

by Mass General BrighamCredit: Unsplash/CC0 Public DomainA collaborative project to bring the promise of cell therapy to patients with a deadly form of brain cancer has shown dramatic results amo

Updated on:March 20,2024

DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

September 15, 2023Caroline SeymourTissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma following disease progression

Updated on: October 11,2023

DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

September 15, 2023Caroline SeymourTissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma following disease progression

Updated on:October 11,2023

ATR inhibition using gartisertib in patient-derived glioblastoma cell lines

by Impact Journals LLCUpregulated genes and pathways enriched in glioblastoma cell lines treated with gartisertib combined with TMZ+RT. Credit:Oncotarget(2024). DOI: 10.18632/oncotarget.28

Updated on: May 11,2024

ATR inhibition using gartisertib in patient-derived glioblastoma cell lines

by Impact Journals LLCUpregulated genes and pathways enriched in glioblastoma cell lines treated with gartisertib combined with TMZ+RT. Credit:Oncotarget(2024). DOI: 10.18632/oncotarget.28

Updated on:May 11,2024

Novel tool helps differentiate between cancerous and healthy cells for AML

Spanish scientists have developed a new method to identify between cancerous and healthy cells for cases of acute myeloid leukaemia (AML).Researchers from Centre for Genomic Regulation (CRG), Spain, h

Updated on: October 31,2023

Novel tool helps differentiate between cancerous and healthy cells for AML

Spanish scientists have developed a new method to identify between cancerous and healthy cells for cases of acute myeloid leukaemia (AML).Researchers from Centre for Genomic Regulation (CRG), Spain, h

Updated on:October 31,2023

Is cold water bad for you? What about drinking from the hose or tap? The facts behind five water myths

by Oliver A.H. Jones,The ConversationCredit: Unsplash/CC0 Public DomainWe know theimportance of staying hydrated, especially in hot weather. But even for something as simple as a drink of

Updated on: May 26,2024

Is cold water bad for you? What about drinking from the hose or tap? The facts behind five water myths

by Oliver A.H. Jones,The ConversationCredit: Unsplash/CC0 Public DomainWe know theimportance of staying hydrated, especially in hot weather. But even for something as simple as a drink of

Updated on:May 26,2024

Brain tumor research could help future precision medicine

byUniversity of BristolCredit: CC0 Public DomainNew research on brain tumors could improve patient diagnosis and treatment options as part of a precision medicine approach. Brain tumors are the

Updated on: December 20,2023

Brain tumor research could help future precision medicine

byUniversity of BristolCredit: CC0 Public DomainNew research on brain tumors could improve patient diagnosis and treatment options as part of a precision medicine approach. Brain tumors are the

Updated on:December 20,2023

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs

byTemple UniversityCredit: CC0 Public DomainLike security screening to make sure nothing harmful makes its way into a crowded area, cells in the human body use checkpoints to control their growt

Updated on: December 20,2023

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs

byTemple UniversityCredit: CC0 Public DomainLike security screening to make sure nothing harmful makes its way into a crowded area, cells in the human body use checkpoints to control their growt

Updated on:December 20,2023

AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia

January 13, 2023Chris RyanMoxetumomab pasudotox-tdfk will be permanently discontinued in the United States market for the treatment of relapsed/refractory hairy cell leukemia.Hairy Cell Leukemia (Kate

Updated on: October 15,2023

AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia

January 13, 2023Chris RyanMoxetumomab pasudotox-tdfk will be permanently discontinued in the United States market for the treatment of relapsed/refractory hairy cell leukemia.Hairy Cell Leukemia (Kate

Updated on:October 15,2023

Researchers identify 'switch' to activate cancer cell death

byUC DavisAntigen-positive tumor cell (blue, left) is a direct target of CAR T-cells (light red) due to high-affinity antibody-antigen contacts. On the contrary, an antigen-negative tumor cell (

Updated on: October 31,2023

Researchers identify 'switch' to activate cancer cell death

byUC DavisAntigen-positive tumor cell (blue, left) is a direct target of CAR T-cells (light red) due to high-affinity antibody-antigen contacts. On the contrary, an antigen-negative tumor cell (

Updated on:October 31,2023

Cevidoplenib Elicits Platelet Responses in Persistent or Chronic Immune Thrombocytopenia

June 11, 2023Chris RyanThe novel SYK inhibitor cevidoplenib dosed at 400 mg twice per day led to robust platelet responses in patients with persistent or chronic primary immune thrombocytopenia who di

Updated on: October 24,2023

Cevidoplenib Elicits Platelet Responses in Persistent or Chronic Immune Thrombocytopenia

June 11, 2023Chris RyanThe novel SYK inhibitor cevidoplenib dosed at 400 mg twice per day led to robust platelet responses in patients with persistent or chronic primary immune thrombocytopenia who di

Updated on:October 24,2023